Description
ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).
Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).
TransfectionReagentforHep-3BCells(HepatocellularCarcinomaCells,HB-8064)
- Ananoparticle-basedliposomeformulation
- Transfectionprotocolsprovidedfortransfectionofproteins,DNA,mRNA,siRNA,shRNAandmicroRNA
- TransfectionEnhancerreagentprovidedwiththekit
- Producehigherlevelofrecombinantproteinexpressionwithminimaldisruptionofnormalcellfunction
- Generatephysiologicallyrelevantdatayoucantrust
- EffectiveforplasmidDNA/siRNAco-transfection
- Easy-to-usetransfectionprotocolwithreproducIBLeresults
- DownloadHep3Btransfectionprotocol:[PDF]
- Download Hep3BCRISPR/Cas9transfectionprotocol:[PDF]
- DownloadPowerPointpresentationforHep3Bcellstransfectionkit:[PPT]
- DevelopedandmanufacturedbyAltogenBiosystems
TransfectionEfficiency:
Reagentexhibitsatleast78%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.
TransfectionProtocolandMSDS:
DownloadAltogenBiosystemsHep3BTransfectionProtocol:[PDF]
DownloadMSDS:[PDF]
Hep-3BCellLine:
Livercancerisatumorthatstartsintheliver,affectingmoreoftenmenthanwomen.AccordingtotheAmericanCancerSociety,over40,000Americansarediagnosedwithlivercancer,andapproximately30,000menandwomenwilldieeveryyearintheUnitedStates,withacontinuous3percentincreaseintheannualmortalityrate.Hepatocellularcarcinoma(HCC)beginsinhepatocellularcellsandisconsideredthemostcommonformoflivercancerinadults,accountingformorethan70%ofalllivermalignancies.HepatomaistheemergenceofmalignanttumorsinpatientswithchronicliverdiseasesandisthethirdleADIngcauseofcancerdeaths,globally.TheHep-3B2.1-7celllinewasestablishedfromthelivertissueofan8-year-oldmalepatientwithhepatocellularcarcinoma.ThesecellscontainHepatitisB.TheHep-3BcelllinehastheHepBvirusintegratedintoitsgenome.Also,Hep-3Bcellsexhibitepithelialmorphologyandareusefulbecausetheymakeanexcellenttransfectionhost(liverBIOLOGicalinvitromodel).Hep-3BcellsareextensivelyusedforliverdiseaseresearchaswellasforcancerandhepatitisBbiomedicalresearch.AltogenBiosystemsmanufacturesnanoparticle-basedtransfectionreagentkitsfortheHep-3Bhepatomacelllinethatthatyieldhightransfectionefficiency.
Data:
![]()
Figure1.GAPDmRNAlevelswerequantifiedusingreal-timeRT-PCRintheHep3BcellstransfectedwithsiRNAstargetingGAPDornon-silencingsiRNA.Forty-eighthourspost-transfection,thecellswereharvestedandanalyzedbyreal-timeRT-PCRforGAPDmRNAexpressionlevels.Datawerenormalizedagainstthe18SrRNAsignal.Controlsampleswereeithermock-transfectedoruntreated.Valuesarenormalizedtountreatedsample.Dataaremeans±SD(n=5).
![]()
Figure2.ProteinexpressionofGAPDHinHep-3Bcells.DNAplasmidexpressingGAPDHorsiRNAtargetingGAPDHweretransfectedintoHep-3BcellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.
Hep-3BTransfectionKit
AltogenBiosystems:
AltogenBiosystemstransfectionandelectroporationproductsforlifesciencesandcancerresearch.Transfectionreagentsaredevelopedforindividualcancercelllineandtransfectionprotocolsareoptimizedformaximumdeliveryefficiency.Advancedformulationofreagentsandoptimizedtransfectionprotocolsprovideefficientintracellulardeliveryofproteins,DNA,mRNA,shRNA,siRNA,andothernegativelychargedbiomoleculesinvitroandinvivo.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.
AltogenLabsResearchServices:
AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BiologyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).
VolumeOptions:
- 0.5ml(Catalog#6817)
- 1.5ml(Catalog#6818)
- 1.5mlCRISPR(Catalog#2152)
- 8.0ml(Catalog#6819)


